Abstract
A combination AIDS vaccine approach consisting of priming with adenovirus-HIV-1MNgp160 recom-binants followed by boosting with HIV-1SF2 gp120 was evaluated in chimpanzees. Long-lasting protection, requiring only three immunizations, was achieved against a low-dose challenge with the SF2 strain of HIV-1 and a subsequent high-dose SF2 challenge administered 1 year later without an intervening boost. Notably, neutralizing antibody responses against both clinical and laboratory isolates developed in three chimpanzees and persisted until the time of high-dose challenge. The possibility that cytotoxic T-lymphocytes contribute to low-dose protection of a chimpanzee lacking neutralizing antibodies is suggested. Our results validate the live vector priming/subunit booster approach and should stimulate interest in assessing this combination vaccine approach in humans.
Similar content being viewed by others
Article PDF
References
Hu, S.L. et al. Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature 328, 721–723 (1987).
Berman, P.W. et al. Human immunodeficiency virus type 1 challenge of chimpanzees immunised with recombinant envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA 85, 5200–5204 (1988).
Arthur, L.O. et al. Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120. J. Virol. 63, 5046–5053 (1989).
Berman, P.W. et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant gp120 but not gp160 glycoproteins. Nature 345, 622–625 (1990).
Girard, M. et al. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 88, 542–546 (1991).
Fultz, P.N. et al. Vaccine protection of chimpanzees against challenge with HIV-1 -infected peripheral blood mononuclear cells. Science 256, 1687–1690 (1992).
Niedrig, M. et al. Immune response of chimpanzees after immunization with the inactivated whole immunodeficiency virus (HIV-1), three different adjuvants and challenge. Vaccine 11, 67–74 (1993).
Bruck, C. et al. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccine 12, 1141–1148 (1994).
Girard, M. et al. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J. Virol. 69, 6239–6248 (1995).
Natuk, R.J. et al. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. AIDS Res. Hum. Retroviruses 9, 395–404 (1993.
Lubeck, M.D. et al. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration [erratum appears in AIDS Res. Hum. Retroviruses 11, 189; 1995]. AIDS Res. Hum. Retroviruses 10, 1443–1449 (1994).
Berman, P.W. et al. et al. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J Infect. Dis. 173, 52–59 (1996).
Girard, M. et al. Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain. J. Virol. 70, 8229–8233 (1996).
Shenk, T. Adenoviridae: The viruses and their replication. in: Fields Virology. (eds. Fields, B.N., Knipe, D.M. & Howley, P.M.) 2111–2148 (Lippincott-Raven, Philadelphia, 1996).
Chapman, B.S., Thayer, R.M., Vincent, K.A. & Haigwood, N.L. Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucleic Acids. Res. 19, 3979–3986 (1991).
Scandella, C.J. et al. Nonaffinity purification of recombinant gp120 for use in AIDS vaccine development. AIDS Res. Hum. Retroviruses 9, 1233–1244 (1993).
Murthy, K.K. et al. Titration of a vaccine stock preparation of human immunodeficiency virus type 1SF2 in cultured lymphocytes and in chimpanzees. AIDS Res. Hum. Retroviruses 12, 1341–1348 (1996).
Zolla-Pazner, S. & Sharpe, S. A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates. AIDS Res. Hum. Retroviruses 11, 1449–1458 (1995).
El-Amad, Z. et al. Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1 SF2. AIDS 9, 1313–1322 (1995).
Stott, E.J. Anti-cell antibody in macaques. Nature 353, 393 (1991).
Arthur, L.O. et al. Cellular proteins bound to immunodeficiency viruses: Implications for pathogenesis and vaccines. Science 258, 1935–1938 (1992).
Arthur, L.O. et al. Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J. Virol. 69, 3117–3124 (1995).
Berman, P.W. et al. Comparison of the immune response to recombinant gp120 in humans and chimpanzees. AIDS 8, 591–601 (1994).
Zarling, J.M. et al. Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins. J. Immunol. 139, 988–990 (1987).
Emini, E.A. et al. Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J. Virol. 64, 3674–3678 (1990.
Emini, E.A. et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355, 728–730 (1992).
Gallimore, A. et al. Early suppression of SIV replication by CD8+nef-specific cytotoxic T cells in vaccinated macaques. Nature Med. 1, 1167–1173 (1995).
Rubin, B.A., Rorke, L.B. Adenovirus vaccines. in Vaccines, (eds. Plotkin, S.A. & Mortimer, E., Jr.) 492–512 (Saunders, Philadelphia, 1988).
Chanda, P.K. et al. High level expression of the envelope glycoproteins of the human immunodeficiency virus type I in presence of rev gene using helper-independent adenovirus type 7 recombinants. Virology 175, 535–547 (1990).
Sorensen, A.B., Duch, M., Jorgensen, P. & Pedersen, F.S. Amplification and sequence analysis of DNA flanking integrated proviruses by a simple two-step polymerase chain reaction method. J. Virol. 67, 7118–7124 (1993).
Lubeck, M.D. et al. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc. Natl. Acad. Sci. USA 86, 6763–6767 (1989).
Robert-Guroff, M. Neutralizing antibodies. in Techniques in HIV Research, (eds. Aldovini, A. & Walker, B.) 179–185 (Stockton, New York, 1990).
Haigwood, N.L. et al. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res. Hum. Retroviruses 6, 855–869 (1990).
Abimiku, A.G. et al. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nature Med. 1, 321–329 (1995).
Clerici, M. et al. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. J. Immunol. 146, 2214–2219 (1991).
Takahashi, H. et al. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 85, 3105–3109 (1998).
Cease, K.B. et al. Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide [published erratum appears in Proc. Natl. Acad. Sci. USA 85, 8226 (1988)]. Proc. Natl. Acad. Sci. USA 84, 4249–4253 (1987).
Doe, B., Steimer, K.S. & Walker, C.M. Induction of HIV-1 envelope (gp120)-specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell-derived gp120 is enhanced by enzymatic removal of N-linked glycans. Eur. J. Immunol. 24, 2369–2376 (1994).
Takahashi, H. et al. A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160. Science 246, 118–121 (1989).
Chakrabarti, S., Brechling, K. & Moss, B. Vaccinia virus expression vector: Coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol. Cell. Biol. 5, 3403–3409 (1985).
Kievits, T. et al. NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. J. Virol. Methods 35, 273–286 (1991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lubeck, M., Natuk, R., Myagkikh, M. et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 3, 651–658 (1997). https://doi.org/10.1038/nm0697-651
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0697-651
This article is cited by
-
Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination
Mucosal Immunology (2010)
-
Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials
Nature Reviews Immunology (2009)
-
INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies
Cancer Gene Therapy (2009)
-
Chimpanzee-origin adenovirus vectors as vaccine carriers
Gene Therapy (2006)
-
Adenovirus as vehicle for anticancer genetic immunotherapy
Gene Therapy (2005)